Impact of Rheumatoid Arthritis on Body Composition, Bone Marrow Adiposity and Bone Mineral Density: a Case-control Study

Who can take part

• Subjects:
• Males and females of age (age ≥ 18 years). Patients with RA according to American College of Rheumatology/EULAR 2010 criteria, Patients who have signed the informed consent
• Controls:
• Males and females of age (age ≥ 18 years). subjects who have signed the informed consent

Who cannot take part

• Patients who have received more than three anti-TNFinhibitors
• Patients who have previously received a Janus kinase (JAK) inhibitor
• Patients with concomitant therapies as described below :; A combination with methotrexate is allowed if methotrexate is started ≥3 months before the start of the study and at a stable dosage (≤25 mg/week) for ≥4 weeks; A combination to conventional synthetic DMARDs (csDMARDs) other than methotrexate is not allowed within 4 weeks before and/or during the clinical trial
• Corticosteroid therapy >10mg/d prednisolone equivalent is not allowed
• Intra-articular injections of corticosteroids are allowed if their number is less than or equal to 4
• Intravenous corticosteroid infusions are not allowed
• Corticosteroid therapy ≥ 10mg/d prednisolone equivalent,
• Pathologies or treatments affecting bone metabolism (breast cancer with antiaromatase, digestive malabsorption, stomach cancer, primary hyperparathyroidism, uncontrolled hyperthyroidism...),
• History of radiotherapy on the lumbar spine or the hip studied,
• Patients undergoing hormone replacement therapy (HRT) or patients already under anti-osteoporotic treatment (bisphosphonates, strontium ranelate, teriparatide or denosumab) apart from calcium and/or vitamin D supplementation, Chronic renal failure with creatinine clearance (CKD-EPI formula) ≤ 30 ml/min,
• History or discovery of an osteoporotic fracture AND/OR T-score ≤-3 if ≥50 years old AND/OR Z-score ≤-3 if <50 years old during the screening phase,
• Immunosuppressants other than methotrexate are not allowed